Shopping Cart 0
Cart Subtotal
AED 0

Adapt Pharma Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Adapt Pharma Ltd (Adapt Pharma) is a drug discovery and development company that manufactures and distributes prescription medicines. The company's product Narcan (naloxone hydrochloride) nasal spray is an opioid antagonist that is indicated for the emergency treatment of opioid overdose as manifested by respiratory and central nervous system depression. It also develops treatments for patients with special medical conditions. Adapt Pharma offers its patients with specialty medical conditions. The company serves firefighters, first responders, law enforcement, and departments of health, educational facilities and community-based organizations, among others. The company has its operations in the US and Ireland. Adapt Pharma is headquartered in Dublin City, Ireland.

Adapt Pharma Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adapt Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Adapt Pharma Enters into Co-Development Agreement with Profector Life Sciences 11

Licensing Agreements 12

Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 12

Equity Offering 13

Adapt Pharma Raises USD95 Million in Private Placement of Shares 13

Acquisition 14

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 14

Adapt Pharma Ltd-Key Competitors 16

Adapt Pharma Ltd-Key Employees 17

Adapt Pharma Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Product News 19

12/20/2017: Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN Nasal Spray for Opioid Overdose 19

11/03/2017: Adapt Pharma Presents Human Factors Study Data on Usability of NARCAN (naloxone HCl) Nasal Spray at the 41st Association for Medical Education & Research in Substance Abuse Annual National Conference 20

10/24/2018: Emergent BioSolutions to offer all public libraries and YMCAs in the U.S. free opioid awareness education and NARCAN (naloxone HCl) Nasal Spray 21

10/24/2017: Walgreens Stocking Life Saving Narcan Nasal Spray in All Pharmacies Nationwide 22

10/17/2017: Adapt Pharma Launches Roll Call Training Video to Educate Law Enforcement on NARCAN (naloxone HCl) Nasal Spray 4mg 23

09/15/2017: Opiant Pharmaceuticals Provides an Update on NARCAN Nasal Spray 24

08/10/2017: Opiant Pharmaceuticals Announces Additional USD 3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization 25

07/12/2018: Aetna Donates Narcan to Wayne County 26

06/26/2018: Albertsons Companies Offers Increased Access to Naloxone 27

06/06/2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose-Current Medical Research and Opinion Journal 28

05/29/2018: ADAPT Pharma Launches New Online Platform for NARCAN 29

05/09/2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program 30

04/30/2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability 31

04/26/2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations 32

04/25/2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities 33

04/24/2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada 34

04/11/2017: Ontario ministries make NARCAN Nasal Spray available to general public 35

04/10/2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities 36

04/09/2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies 37

04/05/2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory 39

04/05/2018: CVS Health Expands Efforts to Educate Patients about Naloxone 40

04/04/2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia 41

03/27/2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray 42

03/19/2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities 43

03/16/2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose 44

03/05/2018: Adapt Pharma Expands Technical and R&D Teams 45

02/28/2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S. 46

02/13/2018: Aptar and Adapt Pharma Donate 5,000 Doses of NARCAN to Opioid Crisis Coalitions in Illinois 47

02/08/2018: Opiant Pharmaceuticals to Record Approximately USD 11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 48

01/31/2018: Aegis Selects NARCAN (naloxone HCl) Nasal Spray to Help Combat Opioid Epidemic, Increasing Access to Life-saving Treatment in LA County 49

01/30/2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas 50

01/26/2017: Opiant Pharmaceuticals Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray 51

01/09/2017: Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN Nasal Spray and Heroin Vaccine Development 52

Product Approvals 53

Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent 53

Jun 27, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent 54

Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents 55

Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray 56

Jan 25, 2017: NARCAN (naloxone HCl) Nasal Spray 2mg Approved by US Food and Drug Administration 57

Clinical Trials 58

Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adapt Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adapt Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adapt Pharma Enters into Co-Development Agreement with Profector Life Sciences 11

Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 12

Adapt Pharma Raises USD95 Million in Private Placement of Shares 13

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 14

Adapt Pharma Ltd, Key Competitors 16

Adapt Pharma Ltd, Key Employees 17

Adapt Pharma Ltd, Subsidiaries 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Adapt Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Adapt Pharma Ltd (Adapt Pharma) is a drug discovery and development company that manufactures and distributes prescription medicines. The company's product Narcan (naloxone hydrochloride) nasal spray is an opioid antagonist that is indicated for the emergency treatment of opioid overdose as manifested by respiratory and central nervous system depression. It also develops treatments for patients with special medical conditions. Adapt Pharma offers its patients with specialty medical conditions. The company serves firefighters, first responders, law enforcement, and departments of health, educational facilities and community-based organizations, among others. The company has its operations in the US and Ireland. Adapt Pharma is headquartered in Dublin City, Ireland.

Adapt Pharma Ltd-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adapt Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Adapt Pharma Enters into Co-Development Agreement with Profector Life Sciences 11

Licensing Agreements 12

Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 12

Equity Offering 13

Adapt Pharma Raises USD95 Million in Private Placement of Shares 13

Acquisition 14

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 14

Adapt Pharma Ltd-Key Competitors 16

Adapt Pharma Ltd-Key Employees 17

Adapt Pharma Ltd-Locations And Subsidiaries 18

Head Office 18

Other Locations & Subsidiaries 18

Recent Developments 19

Product News 19

12/20/2017: Opiant Pharmaceuticals Announces Significant Financial Developments Related to NARCAN Nasal Spray for Opioid Overdose 19

11/03/2017: Adapt Pharma Presents Human Factors Study Data on Usability of NARCAN (naloxone HCl) Nasal Spray at the 41st Association for Medical Education & Research in Substance Abuse Annual National Conference 20

10/24/2018: Emergent BioSolutions to offer all public libraries and YMCAs in the U.S. free opioid awareness education and NARCAN (naloxone HCl) Nasal Spray 21

10/24/2017: Walgreens Stocking Life Saving Narcan Nasal Spray in All Pharmacies Nationwide 22

10/17/2017: Adapt Pharma Launches Roll Call Training Video to Educate Law Enforcement on NARCAN (naloxone HCl) Nasal Spray 4mg 23

09/15/2017: Opiant Pharmaceuticals Provides an Update on NARCAN Nasal Spray 24

08/10/2017: Opiant Pharmaceuticals Announces Additional USD 3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization 25

07/12/2018: Aetna Donates Narcan to Wayne County 26

06/26/2018: Albertsons Companies Offers Increased Access to Naloxone 27

06/06/2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose-Current Medical Research and Opinion Journal 28

05/29/2018: ADAPT Pharma Launches New Online Platform for NARCAN 29

05/09/2018: Quebec Government makes NARCAN Nasal Spray free to anyone 14 years or older through Free naloxone program 30

04/30/2018: A Retrospective Analysis & Literature Review Published in Pain Management on the Pharmacokinetic Properties of Naloxone Approved for Community Use Highlights Bioequivalence of Dose & Usability 31

04/26/2018: Adapt Pharma donates 20,000 doses of NARCAN (naloxone HCl) Nasal Spray to the National Council for Behavioral Health and its Residential Treatment Member Organizations 32

04/25/2018: A Retrospective Literature Review Published in Pain Management on Prescribing Naloxone for Opioid Overdose Intervention Highlights Opportunities to Expand Community Access to Help Reduce Fatalities 33

04/24/2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada 34

04/11/2017: Ontario ministries make NARCAN Nasal Spray available to general public 35

04/10/2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities 36

04/09/2018: Adapt Pharma Welcomes Canadian & Ontario Governments Programs Providing NARCAN (naloxone HCl) Nasal Spray Free of Charge to NIHB Clients and All Ontarians through Pharmacies 37

04/05/2018: ADAPT Pharma Welcomes Surgeon General Naloxone Advisory 39

04/05/2018: CVS Health Expands Efforts to Educate Patients about Naloxone 40

04/04/2018: Cardinal Health Begins Donation of Over 80,000 Doses of Life-Saving Narcan for Distribution to Law Enforcement and First Responders in Appalachia 41

03/27/2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray 42

03/19/2018: ADAPT Pharma Expands Program Offering Free NARCAN (naloxone HCl) Nasal Spray to Eligible Schools and Universities 43

03/16/2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose 44

03/05/2018: Adapt Pharma Expands Technical and R&D Teams 45

02/28/2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S. 46

02/13/2018: Aptar and Adapt Pharma Donate 5,000 Doses of NARCAN to Opioid Crisis Coalitions in Illinois 47

02/08/2018: Opiant Pharmaceuticals to Record Approximately USD 11.7 Million in Royalty and Milestone Payments Related to 2017 Sales of NARCAN Nasal Spray for Opioid Overdose 48

01/31/2018: Aegis Selects NARCAN (naloxone HCl) Nasal Spray to Help Combat Opioid Epidemic, Increasing Access to Life-saving Treatment in LA County 49

01/30/2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas 50

01/26/2017: Opiant Pharmaceuticals Announces FDA Approval of 2mg Formulation of NARCAN (naloxone HCI) Nasal Spray 51

01/09/2017: Opiant Pharmaceuticals Featured in Recent Media Highlighting NARCAN Nasal Spray and Heroin Vaccine Development 52

Product Approvals 53

Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent 53

Jun 27, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent 54

Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents 55

Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray 56

Jan 25, 2017: NARCAN (naloxone HCl) Nasal Spray 2mg Approved by US Food and Drug Administration 57

Clinical Trials 58

Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals 58

Appendix 59

Methodology 59

About GlobalData 59

Contact Us 59

Disclaimer 59


List Of Figure

List of Figures

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Key Facts 2

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Adapt Pharma Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Adapt Pharma Ltd, Deals By Therapy Area, 2012 to YTD 2018 9

Adapt Pharma Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Adapt Pharma Enters into Co-Development Agreement with Profector Life Sciences 11

Lightlake Therapeutics Enters into Licensing Agreement with Adapt Pharma Operations 12

Adapt Pharma Raises USD95 Million in Private Placement of Shares 13

Emergent BioSolutions Acquires Adapt Pharma for USD735 Million 14

Adapt Pharma Ltd, Key Competitors 16

Adapt Pharma Ltd, Key Employees 17

Adapt Pharma Ltd, Subsidiaries 18

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Adapt Pharma Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.